Investors / United States / Westlake BioPartners
Westlake BioPartners
Venture capital · Westlake Village, CA, United States · North America
Westlake BioPartners is a life science venture capital firm that invests in entrepreneurs and incubates companies, providing hands-on support from ideation and preclinical research through clinical and commercial stages. It is based in the Los Angeles biotech community and supports companies in California and beyond.
Invests inHealthcare & Biotech
In its own wordslife sciencesbiotechtherapeuticsincubationdrug discovery
Your fit with Westlake BioPartners
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsWestlake BioPartners lists 16 checked portfolio companies on its own site and is named in 4 funding rounds, 2 of them as lead. Its most frequent entry is Series A, 75% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 92% of its companies are based in United States. It invests most often alongside Sanofi Ventures, Versant Ventures and Agent Capital.
Counts come from funding rounds that name Westlake BioPartners, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Westlake BioPartners' whole history. Rounds on record name 4 companies; its own site lists 16. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundWestlake BioPartners does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 75% |
| Series B | 0% |
| Growth | 25% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 2 | 2 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 39th | 15 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 92th | 20% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 42th | 2 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Sanofi Ventures | 3 |
| Versant Ventures | 3 |
| Agent Capital | 2 |
| Foresite Capital | 2 |
| Kleiner Perkins | 2 |
| New Leaf Venture Partners | 2 |
| RA Capital | 2 |
| SoftBank Vision Fund | 2 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers16100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare Westlake BioPartners head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Westlake BioPartners| Date | Company | Stage |
|---|---|---|
| 17 Jun 2026 | Series A Led | |
| 19 May 2026 | Series A Led | |
| 22 Oct 2025 | Series C+ | |
| 16 Sept 2025 | Series A |
Round details for Westlake BioPartners
Amounts, full round histories and every co-investor in Westlake BioPartners' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
16 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 3T Biosciences is an immunotherapy company developing next-generation therapies for the treatment of solid tumors and other immune-mediated diseases | Healthcare & Biotech | Portfolio page | ||
| Allrock Bio develops therapies for cardio-pulmonary diseases. | Healthcare & Biotech | Sept 2025Series A | Funding round | |
| Alumis Inc is focused on immune-mediated disease therapies | Healthcare & Biotech | Portfolio page | ||
| Arsenal Biosciences, Inc. is a cell therapy company that discovers and develops next-generation in vivo T cell therapies to address chronic disease, including cancer and autoimmunity. | Healthcare & Biotech | Portfolio page | ||
| Borealis Biosciences develops RNA medicines to treat kidney diseases | Healthcare & Biotech | Portfolio page | ||
| Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. | Healthcare & Biotech | Portfolio page | ||
| ELECTRA Therapeutics is developing therapies to improve outcomes for patients with immune-mediated diseases and cancer. | Healthcare & Biotech | Oct 2025Series C+ | Page + round | |
| Kite Pharma develops cell therapies to treat cancer | Healthcare & Biotech | Portfolio page | ||
| Kyverna Therapeutics develops cell therapies for autoimmune diseases | Healthcare & Biotech | Portfolio page | ||
| Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines | Healthcare & Biotech | Portfolio page | ||
| Neuron23 is developing a precision medicine approach to improve the lives of people with Parkinson's disease | Healthcare & Biotech | Portfolio page | ||
| Oorja Bio develops groundbreaking therapies for cardiopulmonary and fibrotic disorders | Healthcare & Biotech | May 2026Series A | Page + round | |
| Recludix is developing new medicines for people living with inflammatory diseases | Healthcare & Biotech | Portfolio page | ||
| STAR Therapeutics discovers and develops antibody therapies for patients with serious diseases | Healthcare & Biotech | Portfolio page | ||
| Sundance Biosciences is developing oral therapies targeting TYK2, an enzyme that plays an important role in regulating the immune system. | Healthcare & Biotech | Portfolio page | ||
| Vedana Therapeutics is developing innovative medicines to help patients achieve migraine freedom. | Healthcare & Biotech | Jun 2026Series A | Page + round |
About this data
site last read 5 Nov 2026- Site
- westlakebio.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 16 Sept 2025
- Companies checked
- 16
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Westlake BioPartners' profile as data
Pull Westlake BioPartners' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/westlakebio.com
# also
GET /v1/firms/westlakebio.com/portfolio
GET /v1/firms/westlakebio.com/coinvestors
GET /v1/firms/westlakebio.com/news